Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients With Severe Traumatic Brain Injury
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Progesterone (Primary)
- Indications Traumatic brain injuries
- Focus Registrational; Therapeutic Use
- Acronyms SyNAPSe
- Sponsors BHR Pharma
- 08 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 08 May 2014 New trial record